150242-82-3

Upstream product

• 94169-62-7 methyl 3,5-di-isopropoxybenzoate 
• 1253732-06-7 3,5-diisopropoxybenzoic acid ethyl ester 
• 99-10-5 3,5-Dihydroxybenzoic acid 
• 4142-98-7 ethyl 3,5-dihydroxybenzoate 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 75-26-3 isopropyl bromide 
• 75-30-9 2-iodo-propane 
• 101508-94-5 3,5-dihydroxybenzoic acid benzyl ester 

Downstream Products

• 1093121-29-9 C₂₄H₂₆N₂O₆S 
• 1093120-99-0 C₂₃H₂₃N₃O₄S 
• 1093120-87-6 C₂₂H₂₃ClN₂O₄S 
• 942999-56-6 N-(tert-butyloxycarbonyl)-3,5-di-(isopropoxy)aniline 
• 1453904-20-5 (Z)-3-(3,5-diisopropoxyphenyl)-2-(4-hydroxyphenyl)acrylonitrile 
• 1453904-21-6 (Z)-3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile 
• 1453904-29-4 (Z)-3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylaldehyde 
• 1453904-34-1 (E)-methyl 3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylate 
• 1453904-37-4 (Z)-methyl 3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylate 
• 1093120-82-1 C₂₃H₂₄N₂O₆S 
• 1093120-86-5 C₂₃H₂₄N₆O₄S 
• 1093120-85-4 C₂₃H₂₅N₃O₅S 
• 1032435-05-4 N-[(3,5-diisopropoxy)phenyl] 4-[(2-amino)ethoxy]-3,5-dimethylbenzamide hydrochloride 
• 1006584-05-9 C₂₈H₄₀N₂O₆ 

Relevant academic research and scientific papers

Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times

Ligand-target residence time is emerging as a key drug discovery parameter because it can reliably predict drug efficacy in vivo. Experimental approaches to binding and unbinding kinetics are nowadays available, but we still lack reliable computational to

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

Design, synthesis, biological and structural evaluation of functionalized resveratrol analogues as inhibitors of quinone reductase 2

Resveratrol (3,5,4′-trihydroxylstilbene) has been proposed to elicit a variety of positive health effects including protection against cancer and cardiovascular disease. The highest affinity target of resveratrol identified so far is the oxidoreductase enzyme quinone reductase 2 (QR2), which is believed to function in metabolic reduction and detoxification processes; however, evidence exists linking QR2 to the metabolic activation of quinones, which can lead to cell toxicity. Therefore, inhibition of QR2 by resveratrol may protect cells against reactive intermediates and eventually cancer. With the aim of identifying novel inhibitors of QR2, we designed, synthesized, and tested two generations of resveratrol analogue libraries for inhibition of QR2. In addition, X-ray crystal structures of six of the resveratrol analogues in the active site of QR2 were determined. Several novel inhibitors of QR2 were successfully identified as well as a compound that inhibits QR2 with a novel binding orientation.

Amphiphilic α-helix mimetics based on a benzoylurea scaffold

The design and synthesis of amphiphilic benzoylurea α-helix mimetics is described. These conformationally constrained molecules allow for the correct angular and spatial projection of hydrophobic and hydrophilic groups and thus the reproduction of side-chains on both faces of an α-helix.

NOVEL ANTI-INFLAMMATORY AGENTS

Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.

IMIDAZOPYRIDINE COMPOUNDS

Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein.

Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator

Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided

1, 3 - DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS

Compounds are provided which are glucokinase activators and thus are useful in treating diabetes and related diseases and have the structure wherein in the ring represents one or two double bonds; R1 is alkyl, aryl, arylalkyl, heteroaryl, or he

THERAPEUTIC COMPOUNDS

This invention relates to a novel class of substituted amino-ethoxy benzene derivatives of formula (I) which are inhibitors of serine proteases and to their use in treating aberrant serine protease activity in a mammal, contraception, anti-coagulant methods and methods for treating aberrant cell proliferation, tumours, cancer, angiogenesis, angiogenesis-based retinopathies, autoimmummune disease, inflammation, skin disease, arthritis, rheutmatoid arthritis, asthma, osteoarthritis and multiple sclerosis. (I), Wherein Rm, Rn, Rp, Rq, V, W, X, Y and R8 are as defined in the claims.

Aspartyl protease inhibitors

The present invention provides compounds having the formula: wherein R1, R′, R2, R3, R3′, R4, X1, X2 and X3 are as defined herein, and pharmaceutical compositions thereof. The present invention also provides methods of inhibiting proteases, more specifically aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer's Disease). The present invention also provides methods for preparing compounds of the invention.